Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17119657 | 0.83 | LYN (0.59) | SRCLYN | |
| SCHEMBL27265461 | 0.83 | USP30 (0.42) | SRCLYNFEN1USP30HPGDS | |
| SCHEMBL27265459 | 0.83 | USP30 (0.42) | SRCLYNFEN1USP30HPGDS | |
| SCHEMBL27265585 | 0.78 | TNK2 (0.42) | SRCLYNUSP30 | |
| SCHEMBL29492674 | 0.74 | PIK3CA (0.62) | PIK3CAKDM4EPKMPRKDC | |
| SCHEMBL620313 | 0.74 | KDM4E (0.53) | USP30HPGDSKDM4EPKMIRAK1 | |
| SCHEMBL2460141 | 0.73 | CCNT1 (0.43) | FEN1USP30HPGDSPARP1PARP2 | |
| SCHEMBL2460139 | 0.73 | CCNT1 (0.43) | FEN1USP30HPGDSPARP1PARP2 | |
| SCHEMBL2461548 | 0.73 | CCNT1 (0.43) | FEN1USP30HPGDSPARP1PARP2 | |
| SCHEMBL16963446 | 0.73 | BTK (0.63) | SRCLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714247-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493454-B2 | Multiple kinase pathway inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MANNKIND CORPORATION | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266870-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | SRC 161/4885LYN 330/4885FEN1 1494/4885 |
| US-20170107215-A1 | MULTIPLE KINASE PATHWAY INHIBITORS | MAP3K6, MAP3K2, MAP3K1 | SRC 161/4885LYN 330/4885FEN1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.